Free Trial
NASDAQ:MGTX

MeiraGTx Q3 2023 Earnings Report

MeiraGTx logo
$8.33 -0.01 (-0.12%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$8.49 +0.16 (+1.92%)
As of 08/14/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.63
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$5.10 million
Expected Revenue
$3.54 million
Beat/Miss
Beat by +$1.56 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

MeiraGTx Earnings Headlines

MeiraGTx reports Q2 EPS (48c) vs (76c) last year
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
MeiraGTx (MGTX) to Release Earnings on Monday
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

View MeiraGTx Profile

More Earnings Resources from MarketBeat